Tumor mutation burden as emerging biomarker in non-small cell lung cancer and beyond

被引：0
作者：
Fischer, Rieke N. [1 ]
Wolf, Juergen [1 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, Cologne, Germany
来源：
TRANSLATIONAL CANCER RESEARCH | 2018年 / 7卷
关键词：
PEMBROLIZUMAB; LANDSCAPE;
D O I：
10.21037/tcr.2018.08.09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S770 / S773
页数：4
相关论文
共 13 条
  • [1] Borghaei H, NIVOLUMAB IPILIMUMAB
  • [2] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [3] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
    Chalmers, Zachary R.
    Connelly, Caitlin F.
    Fabrizio, David
    Gay, Laurie
    Ali, Siraj M.
    Ennis, Riley
    Schrock, Alexa
    Campbell, Brittany
    Shlien, Adam
    Chmielecki, Juliann
    Huang, Franklin
    He, Yuting
    Sun, James
    Tabori, Uri
    Kennedy, Mark
    Lieber, Daniel S.
    Roels, Steven
    White, Jared
    Otto, Geoffrey A.
    Ross, Jeffrey S.
    Garraway, Levi
    Miller, Vincent A.
    Stephens, Phillip J.
    Frampton, Garrett M.
    [J]. GENOME MEDICINE, 2017, 9
  • [4] Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials
    Foster, Nathan R.
    Qi, Yingwei
    Shi, Qian
    Krook, James E.
    Kugler, John W.
    Jett, James R.
    Molina, Julian R.
    Schild, Steven E.
    Adjei, Alex A.
    Mandrekar, Sumithra J.
    [J]. CANCER, 2011, 117 (06) : 1262 - 1271
  • [5] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
  • [6] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
    Hellmann, M. D.
    Ciuleanu, T. -E.
    Pluzanski, A.
    Lee, J. S.
    Otterson, G. A.
    Audigier-Valette, C.
    Minenza, E.
    Linardou, H.
    Burgers, S.
    Salman, P.
    Borghaei, H.
    Ramalingam, S. S.
    Brahmer, J.
    Reck, M.
    O'Byrne, K. J.
    Geese, W. J.
    Green, G.
    Chang, H.
    Szustakowski, J.
    Bhagavatheeswaran, P.
    Healey, D.
    Fu, Y.
    Nathan, F.
    Paz-Ares, L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2093 - 2104
  • [7] Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    Langer, Corey J.
    Gadgeel, Shirish M.
    Borghaei, Hossein
    Papadimitrakopoulou, Vassiliki A.
    Patnaik, Amita
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Jalal, Shadia I.
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Ge, Yang
    Raftopoulos, Harry
    Gandhi, Leena
    [J]. LANCET ONCOLOGY, 2016, 17 (11) : 1497 - 1508
  • [8] Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
    Le, Dung T.
    Durham, Jennifer N.
    Smith, Kellie N.
    Wang, Hao
    Bartlett, Bjarne R.
    Aulakh, Laveet K.
    Lu, Steve
    Kemberling, Holly
    Wilt, Cara
    Luber, Brandon S.
    Wong, Fay
    Azad, Nilofer S.
    Rucki, Agnieszka A.
    Laheru, Dan
    Donehower, Ross
    Zaheer, Atif
    Fisher, George A.
    Crocenzi, Todd S.
    Lee, James J.
    Greten, Tim F.
    Duffy, Austin G.
    Ciombor, Kristen K.
    Eyring, Aleksandra D.
    Lam, Bao H.
    Joe, Andrew
    Kang, S. Peter
    Holdhoff, Matthias
    Danilova, Ludmila
    Cope, Leslie
    Meyer, Christian
    Zhou, Shibin
    Goldberg, Richard M.
    Armstrong, Deborah K.
    Bever, Katherine M.
    Fader, Amanda N.
    Taube, Janis
    Housseau, Franck
    Spetzler, David
    Xiao, Nianqing
    Pardoll, Drew M.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Eshleman, James R.
    Vogelstein, Bert
    Anders, Robert A.
    Diaz, Luis A., Jr.
    [J]. SCIENCE, 2017, 357 (6349) : 409 - 413
  • [9] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
    Lopes, Gilberto
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz
    Cho, Byoung Chul
    Castro, Gilberto
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra A.
    Mok, Tony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [10] Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026
    Peters, Solange
    Creelan, Benjamin
    Hellmann, Matthew D.
    Socinski, Mark A.
    Reck, Martin
    Bhagavatheeswaran, Prabhu
    Chang, Han
    Geese, William J.
    Paz-Ares, Luis
    Carbone, David P.
    [J]. CANCER RESEARCH, 2017, 77
12